Compare MYFW & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MYFW | CHRS |
|---|---|---|
| Founded | 2002 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.7M | 296.8M |
| IPO Year | 2018 | 2014 |
| Metric | MYFW | CHRS |
|---|---|---|
| Price | $28.46 | $1.47 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $27.00 | $5.51 |
| AVG Volume (30 Days) | 25.7K | ★ 1.3M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.02 | ★ 472.00 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $96,914,000.00 | N/A |
| Revenue This Year | $20.48 | $73.08 |
| Revenue Next Year | $9.70 | $30.94 |
| P/E Ratio | $45.24 | ★ N/A |
| Revenue Growth | ★ 7.60 | N/A |
| 52 Week Low | $20.11 | $0.72 |
| 52 Week High | $30.00 | $2.62 |
| Indicator | MYFW | CHRS |
|---|---|---|
| Relative Strength Index (RSI) | 54.30 | 35.29 |
| Support Level | $22.31 | $1.37 |
| Resistance Level | N/A | $1.80 |
| Average True Range (ATR) | 1.04 | 0.11 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 38.57 | 1.55 |
First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.